Adamant Biomedical Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Adamant Biomedical Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$3.25M	Sell	36,000 -14,000	-28%	-$1.16M	0.78%	48
2014 Q3	$3.61M	Buy	+50,000	New	+$3.29M	0.9%	42

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Adamant Biomedical Investments's BMRN Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its BioMarin Pharmaceuticals (BMRN) stake by 28% in Q4 2014, selling an estimated $1.16M and leaving 36,000 shares worth $3.25M. The position accounts for 0.78% of the portfolio, ranked #48.

Adamant Biomedical Investments first reported a position in BMRN in Q3 2014 and has held it in 2 quarters since. The position peaked at $3.61M in Q3 2014. 341 funds tracked by Wall St. Rank hold BMRN as of Q4 2014.

Adamant Biomedical Investments held 36,000 shares of BioMarin Pharmaceuticals worth $3.25M as of Q4 2014.
Adamant Biomedical Investments sold 14,000 BioMarin Pharmaceuticals shares in Q4 2014, an estimated $1.16M.
BioMarin Pharmaceuticals made up 0.78% of Adamant Biomedical Investments's portfolio in Q4 2014, its #48 holding.
Adamant Biomedical Investments first reported a position in BioMarin Pharmaceuticals in Q3 2014 and has held it in 2 quarters since.
Adamant Biomedical Investments's BioMarin Pharmaceuticals position peaked at $3.61M in Q3 2014.
341 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.